CENTAGEN
Dead / Abandoned — Abandoned — no statement of use filed (as of 14 Aug 2025)
What this means for you
This application is over — abandoned 14 Aug 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97464407
- Mark type
- Stylized text
- Filed
- 17 Jun 2022
- Published for opposition
- 19 Dec 2023
- Abandoned
- 14 Aug 2025
- Attorney of record
- Aileen Law
Goods and services
- Class 005 — Pharmaceuticals: Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Pharmaceutical preparations for the treatment of age-related diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular, oncological, immune system and inflammatory related diseases and disorders; Therapeutic pharmaceutical for the treatment of age-related diseases and disorders; Therapeutic pharmaceutical for the treatment of cardiovascular, oncological, immune system and inflammatory related diseases and disorders; Cardiovascular pharmaceutical preparations
Owner
- Centagen, Inc., Boulder, CO, US
- Centagen, Inc., Boulder, CO, US
Prosecution history
- 17 Sept 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 17 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Sept 2025 — CORRECTED NOA E-MAILED
- 16 Sept 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 16 Sept 2025 — SOU EXTENSION 2 GRANTED
- 12 Feb 2025 — SOU EXTENSION 2 FILED
- 16 Sept 2025 — DIVISIONAL PROCESSING COMPLETE
- 13 Feb 2025 — DIVISIONAL REQUEST RECEIVED
- 03 Sept 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 13 Feb 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 30 Apr 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 13 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Aug 2024 — SOU EXTENSION 1 GRANTED
- 12 Aug 2024 — SOU EXTENSION 1 FILED